AFMDQ (Affimed NV) Total Operating Expense: $81.43 Mil (TTM As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AFMDQ Affimed NV AFMDQ
16 GF Score
Price $0.00
View Full Analysis

What is Affimed NV Total Operating Expense?

Affimed NV AFMDQ 16 Total Operating Expense is $81.43 Mil as of Sep. 2024. GuruFocus rates AFMDQ with a GF Score™ of 16/100.

Affimed NV's Total Operating Expense for the three months ended in Sep. 2024 was $16.03 Mil. Affimed NV's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $81.43 Mil.

Affimed NV Total Operating Expense Related Terms

Affimed NV Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Affimed NV's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV Total Operating Expense Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.04 77.08 119.05 138.06 130.22

Affimed NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.69 26.83 21.59 16.97 16.03
AFMDQ
16GF Score
Affimed NV AFMDQ
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Affimed NV Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $81.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $81.43 Mil mean?
Affimed NV (AFMDQ) has a Total Operating Expense of $81.43 Mil as of Sep. 2024. Total operating expense is the primary recurring expense associated with central operations. View historical data on Affimed NV and its competitors.
Is Affimed NV's Total Operating Expense too high?
Affimed NV's current Total Operating Expense is $81.43 Mil. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's Total Operating Expense compare to SYRS and BTAX?
Affimed NV's Total Operating Expense of $81.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Affimed NV and its competitors. Affimed NV's current Total Operating Expense is $81.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current Total Operating Expense of $81.43 Mil. The current Total Operating Expense is $81.43 Mil. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current Total Operating Expense is $81.43 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Affimed NV Business Description

Address Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score

Get the complete analysis for AFMDQ

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price